Ruella, Marco http://orcid.org/0000-0003-4301-5811
Xu, Jun
Barrett, David M.
Fraietta, Joseph A.
Reich, Tyler J. http://orcid.org/0000-0003-0178-1411
Ambrose, David E.
Klichinsky, Michael
Shestova, Olga
Patel, Prachi R.
Kulikovskaya, Irina
Nazimuddin, Farzana
Bhoj, Vijay G.
Orlando, Elena J.
Fry, Terry J. http://orcid.org/0000-0001-8044-5226
Bitter, Hans
Maude, Shannon L.
Levine, Bruce L. http://orcid.org/0000-0001-6971-8465
Nobles, Christopher L.
Bushman, Frederic D.
Young, Regina M.
Scholler, John
Gill, Saar I.
June, Carl H. http://orcid.org/0000-0003-0241-3557
Grupp, Stephan A.
Lacey, Simon F.
Melenhorst, J. Joseph
Article History
Received: 8 March 2018
Accepted: 20 August 2018
First Online: 1 October 2018
Change Date: 23 October 2018
Change Type: Update
Change Details: In the original version of the article, Jun Xu was missing affiliation number 11, indicating an equal contribution, despite being included as an equal contributor in the full list of affiliations. Affiliation number 11 has been added to Jun Xu.
Competing interests
: C.H.J., J.J.M., M.R., J.S., J.A.F., R.M.Y., and S.I.G. work under a research collaboration involving the University of Pennsylvania and the Novartis Institutes of Biomedical Research, Inc. and are inventors of intellectual property (IP) licensed by the University of Pennsylvania to Novartis. C.L.N. has IP in a CART-related patent. B.L.L. is a consultant for CRC Oncology, Cure Genetics, Novartis and a member of the Scientific Advisory Board for Brammer Bio, Incysus, Avectas. B.L.L. is the founder of and has equity in Tmunity Therapeutics and receives Research Funding from Novartis and Tmunity. S.F.L. receives Novartis, Tmunity and Parker Institute for Cancer immunotherapy research funding and has CART-related IP. S.A.G. discloses Novartis research funding and consultancy. E.O. and H.B. are employed by Novartis. All the other authors have no competing interests.